… release (IR) and extended release (ER) formulations, and ER MPH has become increasingly
dominant in recent years [19, 20]. Osmotic release oral system … and equivalent effectiveness …

… An open-label, four-arm, Phase 2a trial to test the efficacy of … accumulated by halophile
bacteria to withstand osmotic stress [Citation58]. … The results of a prospective, active-controlled, …

… al. formulated an osmotic release strategy of cyclosporine via … In a randomized, active-controlled
phase 2/3 study, tregopil … First of all, a prospective, single-center, open-label, phase 1 …

… , based on a prospective comparison, and osmotic-release oral system (OROS)-MPH, based
… these open-label studies were similar to those reported in the short-term randomized trials; …

… of receiving osmotic-release oral system methylphenidate (… head randomized clinical trial
was a 24-week open-label study… Similar findings were noted in the RVIP. The probability of …

… The prescription strategy of methylphenidate here is similar to our clinical practice in Taiwan,
… Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit …

… Arbaclofen extended-release (ER) employs osmotic pump technology to … , randomized
placebo- and active-controlled trial demonstrated that 40 mg/day arbaclofen ER had similar …

… randomly assigned to osmotic-release oral system methylphenidate (n = 83) and atomoxetine
(n = 85) in a 24-week, open-label, head-to-head clinical trial. … have comparable efficacy in …

… , randomized, active-controlled, parallel-group clinical trial was … open-label study comparing
ATX with ‘other standard therapy’ (mainly MPH) [32] and in the osmotic-release oral system …

… of one randomized, placebo- and active-controlled trial of lisdexamfetamine (osmotic-release …
A multi-centre, randomised, open-label study of atomoxetine compared with standard …